NI

Nanologica AB (publ)STO Nanologica AB Stock Report

Last reporting period 30 Sep, 2023

Updated 19 Sep, 2024

Last price

Market cap $B

0.011

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

NICA.ST Stock Analysis

NI

Uncovered

Nanologica AB (publ) is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-11/100

Low score

Market cap $B

0.011

Dividend yield

Shares outstanding

36.146 B

Nanologica AB engages in the research and development of pharmaceutical products. The company is headquartered in Sodertalje, Stockholm. The company went IPO on 2015-10-30. The firm specializes in developing nanoporous materials from nanoporous silica (silicon dioxide) for a variety of applications, ranging from purification to pharmaceutical excipients. The firm's core competency has been developed and expanded in two areas of application, in particular: Drug Delivery and Chromatography, a technology used for the separation and purification of products on the market and in development. The firm's Drug Delivery sector operates within a niche domain of nanocarriers. Nanologica AB (publ)’s drug delivery technology is aimed on absorption of the medicine by the body for drugs that are poorly soluble in water.

View Section: Eyestock Rating